Advertisement

Clonal Analysis of n-ras Gene Activation in Acute Myeloid Leukemia

  • M. Lübbert
  • W. Oster
  • F. McCormick
  • R. Mertelsmann
  • F. Herrmann
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 131)

Abstract

Members of the ras gene family code for 21-kDa proteins (p21) located at the inner cellular membrane. Several lines of evidence suggest that p21 proteins are involved in intracellular signal transduction pathways, thus regulating cellular growth and differentiation. Ras proteins bind and hydrolyze GTP (Gibbs et al. 1984; Sweet et al. 1984) and show sequence homology to G proteins (Hurley et al. 1984) which are thought to participate in the action of some cytokines. The p21 of n-ras has been shown to couple receptor binding of hematopoietic growth factors to inositol lipid hydrolysis in fibroblasts (Wakelam et al. 1986). Conversely, activation of G proteins by sodium fluoride in the presence of Al3+ results in expression of cytokines (Yamato et al. 1989), and expression of an activated ras gene transfected into normal cells or cell lines can induce cytokine expression by these cells (Yiagnisis and Spandidos 1987; Demetri et al. 1988; Andrejauskas and Moroni 1989) and change their responsiveness towards growth factors (Kelekar and Cole 1987; Leof et al. 1987). Point mutations leading to an activated p21 occur in numerous human malignancies (for a review, see Bos 1988). Activating mutations of n-ras have been reported to occur in 25%–40% of cases of acute myelogenous leukemia (AML). (Bos et al. 1985; Janssen et al. 1987; Farr et al. 1988). However, the presence of these mutations can be restricted to subpopulations (subclones) of leukemic cells (Toksoz et al. 1987).

Keywords

Acute Myeloid Leukemia Acute Myelogenous Leukemia Clonal Analysis Activate Point Mutation Soft Agar Culture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andrejauskas E, Moroni C (1989) Reversible abrogation of IL-3 dependence by an inducible H-ras oncogene. EMBO J 8: 2575–2581PubMedGoogle Scholar
  2. Bartram CR, Ludwig WD, Hiddemann W, Lyons J, Buschle M, Ritter J, Harbott J, Fröhlich A, Janssen JWG (1989) Acute myeloid leukemia: analysis of Ras gene mutations and clonality defined by polymorphic x-linked loci. Leukemia 3: 247–256PubMedGoogle Scholar
  3. Begley CG, Metealf D, Nicola NA (1987) Purified colony stimulating factors (G-CSF and GM-CSF) induce differentiation in human HL-60 leukemic cells with suppression of clonogenicity, Int J Cancer 39: 99–105PubMedCrossRefGoogle Scholar
  4. Bos JL (1988) The RAS gene family and human carcinogenesis. Mutation Res 195: 255–271PubMedGoogle Scholar
  5. Bos JL, Toksoz D, Marshall CJ, Verlaan-de Vries M, Veeneman GH, van der Eb AJ, van Boom JH, Janssen JWG, Steenvorden ACM (1985) Amino-acid substitutions at codon 13 of the N-RAS oncogene in human acute myeloid leukemia. Nature 315: 726–730PubMedCrossRefGoogle Scholar
  6. Collins S, Groudine M (1982) Amplification of endogenous myc-related DNA sequences in a human myeloid leukemia cell line. Nature 298: 679–681PubMedCrossRefGoogle Scholar
  7. Dalla-Favera R, Gelman EP, Martinotti S, Franchini G, Papas TS, Gallo RC, Wong-Staal F (1982) Cloning and characterization of different human sequences related to the onco gene (v-myc) of avian myelocytomatosis virus (MC29). Proc Natl Acad Sci USA 79: 6497–6501PubMedCrossRefGoogle Scholar
  8. Demetri GD, Ernst TJ, Pratt ES, Zenzie BW, Rheinwald JG, Griffin JD (1990) Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J Clin Invest 86: 1261–1269PubMedCrossRefGoogle Scholar
  9. Ernst TJ, Gazdar A, Ritz J, Shipp MA (1988) Identification of a second transforming gene, RASn, in a human multiple myeloma line with a rearranged c-myc allele. Blood 72: 1163–1167PubMedGoogle Scholar
  10. Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ (1988) Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci USA 85: 1629–1633PubMedCrossRefGoogle Scholar
  11. Feinberg AP, Vogelstein B (1983) A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Ann Biochem 132: 6–13CrossRefGoogle Scholar
  12. Gibbs JB, Sigal IS, Poe M, Scolnick EM (1984) Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci USA 81: 5704–5708PubMedCrossRefGoogle Scholar
  13. Griffin JD, Young DC, Herrmann F, Wiper D, Wagner K, Sabbath KD (1986) Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 76: 1448–1453Google Scholar
  14. Hardy KJ, Peterlin BM, Atchinson RE, Stobo JD (1985) Regulation of expression of the human interferon alpha gene. Proc Natl Acad Sci USA 82: 8173–8177PubMedCrossRefGoogle Scholar
  15. Hirano T, Taga T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73–75PubMedCrossRefGoogle Scholar
  16. Hurley JB, Simon MI, Teplow DB, Robishaw JD, Gilman AG (1984) Homologies between signal transducing G proteins and ras gene products. Science 226: 860–862PubMedCrossRefGoogle Scholar
  17. Janssen JWG, Steenvoorden ACM, Lyons J, Anger B, Bohlke JU, Bos JL, Seliger H, Bartram CR (1987) RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplasia syndromes. Proc Natl Acad Sci USA 84: 9228–9232PubMedCrossRefGoogle Scholar
  18. Kelekar A, Cole MD (1987) Immortalization by c-myc, H-ras, and Ela oncogenes induces differential cellular gene expression and growth factor responses. Mol Cell Biol 7: 3899–3907PubMedGoogle Scholar
  19. Land H, Parada LF, Weinberg RA (1983) Tumorigenic conversion of primary embryo fibroblast requires at least two cooperating oncogenes. Nature 304: 596–602PubMedCrossRefGoogle Scholar
  20. Leof EB, Proper JA, Moses HL (1987) Modulation of transforming growth factor type beta action by activated ras and c-myc. Mol Cell Biol 7: 2649–2652PubMedGoogle Scholar
  21. Lübbert M, Mirro Jr J, Kahan J, Miller CW, Isaac G, Kitchingman G, Mertelsmann R, Herrmann F, McCormick F, Koeffler HP (1990) N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 75: 1163–1169PubMedGoogle Scholar
  22. Mallet M, Mane SM, Meltzer S, Needleman SW (1989) C-myc amplification coexisting with N-ras point mutation in the biphenotypic cell line RED-3. Leukemia 7: 511–515Google Scholar
  23. Murray MJ, Cunningham JM, Parada LF, Duatry F, Lebowitz P, Weinberg RA (1983) The HL-60 transforming sequence: a RAS oncogene coexisting with altered myc genes in hematopoietic tumors. Cell 33: 749–757PubMedCrossRefGoogle Scholar
  24. Noda M, Ko M, Ogura A, Liu DG, Amano T, Takano T, Ikawa I (1985) Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in a neuronal cell line. Nature 318: 73–75PubMedCrossRefGoogle Scholar
  25. Olson EN, Spizz G, Tainsky MA (1987) The oncogenic forms of N-ras or H-ras prevent skeletal myoblast differentiation. Mol Cell Biol 7: 2104–2111PubMedGoogle Scholar
  26. Oster W, Cicco NA, Klein H, Hirano T, Kishimoto T, Lindemann A, Mertelsmann RH, Herrmann F (1989) Participation of the cytokines Interleukin 6, tumor necrosis factor-alpha, and Interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 84: 451–457PubMedCrossRefGoogle Scholar
  27. Saiki R, Scharf S, Faloona F, Mullis K, Horn G, Erlich HA, Arnheim N (1985) Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230: 1350–1353PubMedCrossRefGoogle Scholar
  28. Seremetis S, Inghirami G, Ferrero D, Dalla-Favera R (1989) Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by RAS oncogenes. Science 243: 660–663PubMedCrossRefGoogle Scholar
  29. Sweet RW, Yokoyama S, Kamata T, Feramisco JR, Rosenberg M, Gross M (1984) The product of RAS is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311: 273–275PubMedCrossRefGoogle Scholar
  30. Toksoz D, Farr CJ, Marshall CJ (1987) ras gene activation in a minor proportion of the blast population in acute myeloid leukemia. Oncogene 1: 409–413PubMedGoogle Scholar
  31. Tomonaga M, Golde DW, Gasson JC (1986) Biosynthetic (recombinant) human granulocyte-macrophage colony stimulating factor: effect on normal bone marrow and leukemic cell lines. Blood 67: 31–36PubMedGoogle Scholar
  32. Wakelam MJO, Davies SA, Houslay MD, McKay I, Marshall CJ, Hall A (1986) Normal p21N-ras couples bombesin and other growth factor receptors to inositol phosphate production. Nature 323: 173–176PubMedCrossRefGoogle Scholar
  33. Yamato K, El-Hajjaoui Z, Kuo JF, Koeffler HP (1989) Granulocyte-macrophage colony-stimulating factor: signals for its mRNA accumulation. Blood 74: 1314–1320PubMedGoogle Scholar
  34. Yiagnisis M, Spandidos DA (1987) Interleukin-3 like activity secreted from human RAS or MYC transfected rodent cells. Anticancer Res 7: 1293–1298PubMedGoogle Scholar
  35. Yunis JJ, Boot AJM, Mayer MG, Bos JL (1989) Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene 4: 609–614PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • M. Lübbert
    • 1
  • W. Oster
    • 2
  • F. McCormick
    • 3
  • R. Mertelsmann
    • 1
  • F. Herrmann
    • 4
  1. 1.Department of Internal Medicine 1University of Freiburg Medical CenterFreiburgFed. Rep. of Germany
  2. 2.Behringwerke AGMarburgFed. Rep. of Germany
  3. 3.Cetus CorporationEmeryvilleUSA
  4. 4.Department of Medical Oncology and Applied Molecular Biology, UKRVFree University of BerlinBerlinGermany

Personalised recommendations